Novo Nordisk stock rose Wednesday after the drugmaker reported quarterly earnings above analysts’ expectations, but forecast ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Second, the medicine everyone thought would take over the industry, Novo Nordisk's CagriSema, did not perform as well as expected in a phase 3 study. CagriSema could still be a commercial success ...

Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely driven by strong demand in the United States.

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

Finally, some good news for Novo Nordisk (NYSE: NVO ... (Which is to say, you take a shot once a week.) Studied over 36 weeks, in doses from 1.25 mg to 20 mg, patients taking amycretin experienced ...

(Bloomberg) -- Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the ...

(Bloomberg) — Novo Nordisk A/S (NVO, NOVO-B.CO) investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back ...